



EGFR Resisters RESEARCH SUMMIT

November 13–15, 2021
Virtual Meeting
ceconcepts.com/egfrsummit

CALL FOR ABSTRACTS

ELIGIBILITY

DEADLINE EXTENDED

- North American-based Junior Faculty and Fellows (MDs, MD/PhDs) involved in research related to *EGFR*-mutated adenocarcinoma of the lungs. We encourage thoracic oncologists, surgeons, radiation oncologists, pathologists, and related lab-based and translational researchers to submit!

1. Junior Faculty (Instructors or Assistant Professors)

2. Trainee (Must be enrolled in an ACGME-accredited fellowship program or PhD postdoctoral fellowship)

- Candidates must be based in North America and training must be completed at a North American-based institution.
- All work must be unpublished original research in an area related to *EGFR*-mutated adenocarcinoma of the lungs. If your research has been disrupted due to COVID-19, we will also accept a Career Statement highlighting your goals and trajectory as related to this area, previously published information, journal club presentation, or other like projects representing professional development.
- Abstracts to be presented at future medical meetings are eligible for submission.

ABSTRACT POLICIES AND PROCEDURES

- Only one abstract submission per Young Investigator will be accepted.
- Abstracts must conform to the abstract preparation instructions. Those that do not may be rejected.
- Only original work completed by the Young Investigator will be accepted.
- All accepted abstracts will be published in an electronic program to be provided to all attendees. The publication of electronic handout materials will not preclude publication or presentation elsewhere.

SELECTION PROCESS

Submission deadline is September 15, 2021

- Expert Faculty Judges will review and score all submissions. Number of abstracts to be selected for presentation will depend on quantity and quality of abstracts received.
- All presentations will be conducted via videoconferencing, should include a modest number of slides, and will consist of a formal presentation with Q&A period for a maximum of 15 total minutes.

ABSTRACT SUBMISSION DEADLINE

All abstracts must be received by 11:59 PM ET on **Wednesday, September 22, 2021**.

2021 AREAS OF INTEREST

- Biology, biomarkers, mutation subtypes and co-mutations
- Adjuvant and neo-adjuvant approaches
- Management of advanced disease including acquired resistance
- Management of CNS metastases and LMD
- Radiation approaches including consolidation and oligoprogression
- Long term effects of therapy, quality of life and advocacy
- Equity and disparities



INSTRUCTIONS FOR ABSTRACT PREPARATION AND SUBMISSION

1. Submission: Please visit www.ceconcepts.com/egfrsummit to complete the abstract submission.

2. Identification: Upon entering the abstract submission website, you will be required to submit the following information:

- Full name, degree(s), credential(s)
- Mailing address
- Daytime telephone and e-mail
- Current institution
- Previous institution (where research was conducted, if applicable)
- Submitting author type: (Junior Faculty or Trainee)

3. Format: Abstracts should be uploaded as a Microsoft Word document with your last name in the document name.

Abstracts should consist of a brief title (bolded) descriptive of the research. Include first and last names and degrees of the authors. Underline the presenting author's name and list the name and location of the institution where research was completed. Do not identify authors or institutions in the body of the abstract. Sans serif font (such as Arial or Helvetica) is preferred. Do not use font sizes smaller than 10 point.

Abstract text must be 1,000 words or less. Please make sure all figures are high resolution (at least 300 dpi). No more than a total of 4 figures and/or tables per submission are permitted. Please limit figures to 1 graph or image each (i.e., no multiple-part figures). Legends should be included with the abstract text and not as part of the figures (not included in the 1,000-word limit); figures should be embedded in the abstract file and not included as separate attachments.

Organize the body of the abstract in the following manner:

- a) Disclosure of relevant financial relationships (not included in word count)
- b) A sentence stating the purpose of the study
- c) A brief statement of methods
- d) A summary of results
- e) A statement of conclusions reached.

4. Notification

Abstract Receipt:

An automatic notice confirming abstract submission, *"Thank you, your submission has been received,"* will be provided upon completion of the online submission process.

Abstract Acceptance:

Notification of abstract acceptance or rejection will be provided to you via e-mail by the first half of October.

FINALISTS

Young Investigators who are selected to present at the live, virtual meeting will be provided with the following in advance:

- Full tech support for video conferencing with technical assessment of computer equipment, camera, audio, software.
- One-on-one coaching to improve scientific presentation skills and ability to respond to challenges & questions.
- Virtual care package with resources to improve camaraderie and effectiveness for the virtual meeting.

AWARDS

An awards ceremony will be held at the completion of the meeting, at which time the award winners (grants ranging from \$500–\$10,000) will be announced.

Grant payments will be made to the affiliated institution of each winning Young Investigator after the live program date.

QUESTIONS

Please contact **Rebecca Weaver, CHCP** with CEC Oncology at weaverr@ceconcepts.com.

Presented by EGFR Resisters and Creative Educational Concepts, LLC.



Supported by an independent educational grant from AstraZeneca.